Natalia Geyvandova

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto et al. · New England Journal of Medicine · 2023 · 188 citations · Full text

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial

Heiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov et al. · The Lancet Infectious Diseases · 2022 · 138 citations

Hepatology, Viral Hepatitis, Pharmacology +9

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

Man‐Fung Yuen, Tarik Asselah, Ira M. Jacobson et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 64 citations

Ide Analogues, Viral Hepatitis, Medicine +10

The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities

М. V. Maevskaya, Yu. V. Kotovskaya, Natalia Geyvandova et al. · Terapevticheskii arkhiv · 2022 · 54 citations · Full text

Main Comorbidities, Pathology, Fatty Liver Disease +26

Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial

Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto et al. · Journal of Hepatology · 2024 · 52 citations · Full text